The Sunshine Act requires manufacturers of drugs, devices, biologicals, and medical supplies to begin recording all physician payments—including payments made for clinical trial research
The FDA is encouraging electronic source data for clinical investigations. This presentation looks at the intentions of the guidance, related regulations and guidelines, understanding new clarified definitions, and what this new guidance means to DATARAK and other EDC vendors being eSource compliant.
In the clinical trials industry, profitability and regulatory compliance pressures continue to mount. Consequently, pharmaceutical companies are striving to maximize their research and development spending by reducing clinical trial cycle times and focusing on their core competencies—all while maintaining high standards of quality. By James M. Dicesare and Kevin T.Williams, Clinical Financial Services, LLC (CFS).
Effective auditing of eClinical trials provides objective evidence to sponsors and supervisory agencies that trial data has been collected according to established policies and procedures safeguarding data quality, security and privacy. In this article, PHT Director of Quality Management & Compliance Rod Thorell and Laura Araujo, Senior Consultant of Quality Management at Halloran Consulting Group, discuss the importance of auditing, explain how it is conducted, and review contemporary issues of auditing. By PHT Corporation
Mobile nursing for a clinical trial is performed by a qualified nurse at an alternate location (home, office, vacation) requiring the same data quality and subject safety as on site visits. By offering mobile visits for clinical trials, the site can see improvement in patient recruitment, patient retention and compliance, expanded geographic reach and increased subject convenience.
Sponsor companies are increasingly required to employ methods for patient-reported outcomes (PROs) that ensure timely, accurate and attributable data collection, as well as to improve patient compliance.
During clinical drug development there can be several situations where the use of radiolabeled medication or other radiolabeled compounds is required or favorable to accomplish the study objectives. This whitepaper is mainly focusing on human ADME studies and “microdose” studies to assess absolute bioavailability (BA). The major part of the information in this overview is also relevant for other clinical studies with a radiolabeled compound. By Ad Roffel and Henk Poelman, PRA Health Sciences
|
|
|
|
|
|
|
|
|